Show simple item record

dc.contributor.authorHamidi, Ahd
dc.contributor.authorHoeksema, Femke
dc.contributor.authorVelthof, Pim
dc.contributor.authorLemckert, Angelique
dc.contributor.authorGillissen, Gert
dc.contributor.authorLuitjens, Alfred
dc.contributor.authorBines, Julie E.
dc.contributor.authorPullagurla, Swathi R.
dc.contributor.authorKumar, Prashant
dc.contributor.authorVolkin, David B.
dc.contributor.authorJoshi, Sangeeta B.
dc.contributor.authorHavenga, Menzo
dc.contributor.authorBakker, Wilfried A.M.
dc.contributor.authorYallop, Christopher
dc.date.accessioned2021-12-22T21:55:59Z
dc.date.available2021-12-22T21:55:59Z
dc.date.issued2021-04-08
dc.identifier.citationHamidi, A., Hoeksema, F., Velthof, P., Lemckert, A., Gillissen, G., Luitjens, A., Bines, J. E., Pullagurla, S. R., Kumar, P., Volkin, D. B., Joshi, S. B., Havenga, M., Bakker, W., & Yallop, C. (2021). Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine. Vaccine, 39(15), 2048–2059. https://doi.org/10.1016/j.vaccine.2021.03.033en_US
dc.identifier.urihttp://hdl.handle.net/1808/32311
dc.description.abstractDespite solid evidence of the success of rotavirus vaccines in saving children from fatal gastroenteritis, more than 82 million infants worldwide still lack access to a rotavirus vaccine. The main barriers to global rotavirus vaccine coverage include cost, manufacturing capacity and suboptimal efficacy in low- and lower-middle income countries. One vaccine candidate with the potential to address the latter is based on the novel, naturally attenuated RV3 strain of rotavirus, RV3-BB vaccine administered in a birth dose strategy had a vaccine efficacy against severe rotavirus gastroenteritis of 94% at 12 months of age in infants in Indonesia. To further develop this vaccine candidate, a well-documented and low-cost manufacturing process is required. A target fully loaded cost of goods (COGs) of ≤$3.50 per course of three doses was set based on predicted market requirements. COGs modelling was leveraged to develop a process using Vero cells in cell factories reaching high titers, reducing or replacing expensive reagents and shortening process time to maximise output. Stable candidate liquid formulations were developed allowing two-year storage at 2–8 °C. In addition, the formulation potentially renders needless the pretreatment of vaccinees with antacid to ensure adequate gastric acid neutralization for routine oral vaccination. As a result, the formulation allows small volume dosing and reduction of supply chain costs. A dose ranging study is currently underway in Malawi that will inform the final clinical dose required. At a clinical dose of ≤6.3 log10 FFU, the COGs target of ≤$3.50 per three dose course was met. At a clinical dose of 6.5 log10 FFU, the final manufacturing process resulted in a COGs that is substantially lower than the current average market price, 2.44 USD per dose. The manufacturing and formulation processes were transferred to BioFarma in Indonesia to enable future RV3-BB vaccine production.en_US
dc.publisherElsevieren_US
dc.rightsCopyright 2021 Batavia Biosciences BV. Published by Elsevier Ltd. This is an open access article under the CC BY licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectOral rotavirus vaccineen_US
dc.subjectFixed bed bioreactoren_US
dc.subjectManufacturing processen_US
dc.subjectCost-of-goods modellingen_US
dc.subjectStable liquid formulationen_US
dc.titleDeveloping a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccineen_US
dc.typeArticleen_US
kusw.kuauthorPullagurla, Swathi R.
kusw.kuauthorKumar, Prashant
kusw.kuauthorVolkin, David B.
kusw.kuauthorJoshi, Sangeeta B.
kusw.kudepartmentPharmaceutical Chemistryen_US
dc.identifier.doi10.1016/j.vaccine.2021.03.033en_US
kusw.oaversionScholarly/refereed, publisher versionen_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.identifier.pmidPMC8062787en_US
dc.rights.accessrightsopenAccessen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Copyright 2021 Batavia Biosciences BV. Published by Elsevier Ltd. This is an open access article under the CC BY license
Except where otherwise noted, this item's license is described as: Copyright 2021 Batavia Biosciences BV. Published by Elsevier Ltd. This is an open access article under the CC BY license